Asian CPP needs continue but flexibility improving
This article was originally published in Scrip
The need to provide certificates of pharmaceutical product (CPP) to many drug regulatory authorities in Asia is seen by some in the industry as a major hindrance to the simultaneous global development of new drugs. But views from regional regulators at a recent Asia-Pacific Economic Cooperation (APEC) symposium suggest that there is little prospect of the requirement disappearing anytime soon.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.